Pfizer Eyes Three Oncology Biosimilar Launches In 2019 As Sterile Injectables Problems Persist

 
• By Dean Rudge

Pfizer’s long-standing sterile injectable supply and manufacturing issues pummelled respective sales in the US in 2018. But the US-based multinational is eyeing a string of oncology biosimilar launches in 2019, which could see biosimilar sales tick past US$1 billion.

PfizerHQ
Will Pfizer see US$1bn of biosimilar sales in 2019? • Source: Shutterstock

More from Biosimilars

More from Products